SL-052
SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical testing for cancer photodynamic therapy (PDT) . SL-052 is encapsulated in biodegradable polylactic-co-glycolic acid (PLGA) polymer nanoparticles optimized using single emulsion solvent evaporation technology. The SL-052-PLGA nanoparticles were more effective in PDT treatment of subcutaneous SCCVII squamous cell carcinoma compared to polyvinylpyrrolidone (PVP) -based and standard liposomal SL-052 formulations. A longer time interval between drug injection and tumor illumination can improve tumor cure rates, and SL-052-PLGA nanoparticles showed the best therapeutic effect among all SL-052 formulations.
Product Specifications
CAS Number
925438-34-2
UNSPSC
12352005
Target
Photosensitizer
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sl-052.html
Smiles
COC(C([C@H](C(C)=CC1=C(N[C@](CCCC2)([H])[C@@]2([H])N3)C3=C4C5=O)C(C)=O)=C6C1=C4C(C(OC)=C5)=C7C6=C8C(C=C7OC)=O)=C8O
Molecular Formula
C35H32N2O7
Molecular Weight
592.64
References & Citations
[1]Antitumor Efficacy of Photodynamic Therapy Using Novel Nanoformulations of Hypocrellin Photosensitizer SL052
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Fam174a (NM_001012350) Rat Tagged ORF Clone Lentiviral Particle
![Rabbit Polyclonal HINT3 Antibody [DyLight 350]](https://cdn.genprice.uk/genprice/uk/genprice4.webp)
Mknk2, NT (Mknk2, Mnk2, MAP kinase-interacting serine/threonine-protein kinase 2, MAP kinase signal-integrating kinase 2) (MaxLight 405)
Mknk2, NT (Mknk2, Mnk2, MAP kinase-interacting serine/threonine-protein kinase 2, MAP kinase signal-integrating kinase 2) (MaxLight 405)